Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
Top Cited Papers
- 1 October 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (13), 1295-1305
- https://doi.org/10.1016/s1470-2045(15)00193-x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidBlood, 2011
- Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Blood, 2010
- Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemiaProceedings of the National Academy of Sciences of the United States of America, 2009
- Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter StudyJournal of Clinical Oncology, 2006
- Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemiaPublished by American Society of Hematology ,2006
- Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemiaBlood, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemiaBlood, 2003
- All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolBlood, 2002
- Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemiaBlood, 2002